Intersect Ent Inc
NASDAQ:XENT
Intersect Ent Inc
Cash & Cash Equivalents
Intersect Ent Inc
Cash & Cash Equivalents Peer Comparison
Competitive Cash & Cash Equivalents Analysis
Latest Figures & CAGR of Competitors
Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Intersect Ent Inc
NASDAQ:XENT
|
Cash & Cash Equivalents
$25.6m
|
CAGR 3-Years
44%
|
CAGR 5-Years
19%
|
CAGR 10-Years
N/A
|
|
Becton Dickinson and Co
NYSE:BDX
|
Cash & Cash Equivalents
$2.3B
|
CAGR 3-Years
-14%
|
CAGR 5-Years
28%
|
CAGR 10-Years
3%
|
|
Boston Scientific Corp
NYSE:BSX
|
Cash & Cash Equivalents
$2.3B
|
CAGR 3-Years
5%
|
CAGR 5-Years
76%
|
CAGR 10-Years
28%
|
|
Stryker Corp
NYSE:SYK
|
Cash & Cash Equivalents
$2.3B
|
CAGR 3-Years
1%
|
CAGR 5-Years
7%
|
CAGR 10-Years
5%
|
|
Abbott Laboratories
NYSE:ABT
|
Cash & Cash Equivalents
$6.3B
|
CAGR 3-Years
-8%
|
CAGR 5-Years
16%
|
CAGR 10-Years
12%
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Cash & Cash Equivalents
$2.8B
|
CAGR 3-Years
27%
|
CAGR 5-Years
27%
|
CAGR 10-Years
13%
|
See Also
What is Intersect Ent Inc's Cash & Cash Equivalents?
Cash & Cash Equivalents
25.6m
USD
Based on the financial report for Mar 31, 2022, Intersect Ent Inc's Cash & Cash Equivalents amounts to 25.6m USD.
What is Intersect Ent Inc's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 5Y
19%
Over the last year, the Cash & Cash Equivalents growth was 78%. The average annual Cash & Cash Equivalents growth rates for Intersect Ent Inc have been 44% over the past three years , 19% over the past five years .